The company expects the decentralised model to at least double its annual testing volume to around 6,000 from the current 3,000
<iframe src="https://hindustansphere.com/embed/cluster/02ae4197d5105448742e398c433cab89fa186ba2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="OncoStem eyes wider access to breast cancer risk test with hospital-use kit"></iframe>
Bengaluru company expects annual volumes to double as decentralised test lowers logistical barriers to personalised treatment
